The Festival of Biologics returns to Basel on 15-17 October as Europe’s leading biologics event, with content covering the discovery and development of antibody and immuno-therapeutics, biosimilars, clinical trials and manufacturing and bioprocessing to explore the start-to-finish of the entire biologics industry.

This year we are delighted to be able to provide FREE passes for all Novartis employees, offering full access to the conference!
 
 

Novartis at Festival of Biologics

Novartis will be contributing sessions across the entire programme – see who will be speaking below:
 

15 October

 


11:55 - 12:20

Joshi Venugopal
Head of Region Europe, Novartis Gene Therapy & Rare Diseases, Senior VP
 
Immunotherapy Keynotes
 
 


12:20 - 13:00

Angela Vollstedt
Global Director, Cell and Gene Therapies Portfolio Management
 
Immunotherapy Keynotes
Cutting-edge innovations in immunotherapies panel 
 
 


15:40 - 16:00

Victor Le
Senior Expert Science and Technology
 
CMC and Developability
 
 

16 October

 


14:40-15:00

Darko Skegro
Associate Director- Group Head Biotherapeutic Engineering and Gene Therapy
 
Protein Engineering
 
 


15:20-15:40

Theodora Weisz
Head of Patient Advocacy and Government Affairs, EMEA
 
Gene Therapy
 
 


17:10-17:30

David Ausländer
Senior Principal Scientist / Group Head
 
Upstream Processing and Cell Line Development
 
 

17 October

 


9:30-9:55

Thomas Hach
Director of Healthcare Systems
 
Immunotherapy Keynotes
 
 


9:40-10:00

Isabelle Petit-Topin
Team/Lab Lead in Downstream Process
 
Downstream processing
What makes your antibodies happy if not (anti-)genius purification
 
 


11:20-11:40

Nicolas Lebesgue
Principal Scientist - Analytical Characterization
 
Analytics and Screening
 
 


11:40-12:00

Thierry Besson
Senior Scientist
 
Mass Spectrometry
New mass spectrometry methodology to analyze emerging biotherapeutics
 
 


12:40-13:00

Tanima Bose
Senior Principal Scientist, Analytical Lead
 
Analytics and Screening
 
 
 
 
 
Offer applies to Novartis employees only. All guest pass applications subject to Terrapinn approval